133 related articles for article (PubMed ID: 16303301)
1. Synthesis of 2,5-thiazole butanoic acids as potent and selective alpha(v)beta3 integrin receptor antagonists with improved oral pharmacokinetic properties.
Wendt JA; Wu H; Stenmark HG; Boys ML; Downs VL; Penning TD; Chen BB; Wang Y; Duffin T; Finn MB; Keene JL; Engleman VW; Freeman SK; Hanneke ML; Shannon KE; Nickols MA; Steininger CN; Westlin M; Klover JA; Westlin W; Nickols GA; Russell MA
Bioorg Med Chem Lett; 2006 Feb; 16(4):845-9. PubMed ID: 16303301
[TBL] [Abstract][Full Text] [Related]
2. Convergent, parallel synthesis of a series of beta-substituted 1,2,4-oxadiazole butanoic acids as potent and selective alpha(v)beta3 receptor antagonists.
Boys ML; Schretzman LA; Chandrakumar NS; Tollefson MB; Mohler SB; Downs VL; Penning TD; Russell MA; Wendt JA; Chen BB; Stenmark HG; Wu H; Spangler DP; Clare M; Desai BN; Khanna IK; Nguyen MN; Duffin T; Engleman VW; Finn MB; Freeman SK; Hanneke ML; Keene JL; Klover JA; Nickols GA; Nickols MA; Steininger CN; Westlin M; Westlin W; Yu YX; Wang Y; Dalton CR; Norring SA
Bioorg Med Chem Lett; 2006 Feb; 16(4):839-44. PubMed ID: 16298127
[TBL] [Abstract][Full Text] [Related]
3. Tricyclic pharmacophore-based molecules as novel integrin alpha(v)beta3 antagonists. Part III: synthesis of potent antagonists with alpha(v)beta3/alpha(IIb)beta3 dual activity and improved water solubility.
Ishikawa M; Hiraiwa Y; Kubota D; Tsushima M; Watanabe T; Murakami S; Ouchi S; Ajito K
Bioorg Med Chem; 2006 Apr; 14(7):2131-50. PubMed ID: 16307881
[TBL] [Abstract][Full Text] [Related]
4. Tricyclic pharmacophore-based molecules as novel integrin alpha(v)beta3 antagonists. Part 1: design and synthesis of a lead compound exhibiting alpha(v)beta3/alpha(IIb)beta3 dual antagonistic activity.
Kubota D; Ishikawa M; Yamamoto M; Murakami S; Hachisu M; Katano K; Ajito K
Bioorg Med Chem; 2006 Apr; 14(7):2089-108. PubMed ID: 16309911
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of pyrazoles and isoxazoles as potent alpha(v)beta3 receptor antagonists.
Penning TD; Khilevich A; Chen BB; Russell MA; Boys ML; Wang Y; Duffin T; Engleman VW; Finn MB; Freeman SK; Hanneke ML; Keene JL; Klover JA; Nickols GA; Nickols MA; Rader RK; Settle SL; Shannon KE; Steininger CN; Westlin MM; Westlin WF
Bioorg Med Chem Lett; 2006 Jun; 16(12):3156-61. PubMed ID: 16621534
[TBL] [Abstract][Full Text] [Related]
6. Tricyclic pharmacophore-based molecules as novel integrin alpha(v)beta3 antagonists. Part 2: synthesis of potent alpha(v)beta3/alpha(IIb)beta3 dual antagonists.
Ishikawa M; Kubota D; Yamamoto M; Kuroda C; Iguchi M; Koyanagi A; Murakami S; Ajito K
Bioorg Med Chem; 2006 Apr; 14(7):2109-30. PubMed ID: 16309912
[TBL] [Abstract][Full Text] [Related]
7. Piperidine-containing beta-arylpropionic acids as potent antagonists of alphavbeta3/alphavbeta5 integrins.
De Corte BL; Kinney WA; Liu L; Ghosh S; Brunner L; Hoekstra WJ; Santulli RJ; Tuman RW; Baker J; Burns C; Proost JC; Tounge BA; Damiano BP; Maryanoff BE; Johnson DL; Galemmo RA
Bioorg Med Chem Lett; 2004 Oct; 14(20):5227-32. PubMed ID: 15380233
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and biological evaluation of novel potent and selective alphavbeta3/alphavbeta5 integrin dual inhibitors with improved bioavailability. Selection of the molecular core.
Marugán JJ; Manthey C; Anaclerio B; Lafrance L; Lu T; Markotan T; Leonard KA; Crysler C; Eisennagel S; Dasgupta M; Tomczuk B
J Med Chem; 2005 Feb; 48(4):926-34. PubMed ID: 15715463
[TBL] [Abstract][Full Text] [Related]
9. Novel potent and selective alphavbeta3/alphavbeta5 integrin dual antagonists with reduced binding affinity for human serum albumin.
Raboisson P; Manthey CL; Chaikin M; Lattanze J; Crysler C; Leonard K; Pan W; Tomczuk BE; Marugán JJ
Eur J Med Chem; 2006 Jul; 41(7):847-61. PubMed ID: 16697080
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of novel platelet fibrinogen receptor antagonists with 2H-1,4-benzoxazine-3(4H)-one scaffold. A systematic study.
Anderluh M; Cesar J; Stefanic P; Kikelj D; Janes D; Murn J; Nadrah K; Tominc M; Addicks E; Giannis A; Stegnar M; Dolenc MS
Eur J Med Chem; 2005 Jan; 40(1):25-49. PubMed ID: 15642407
[TBL] [Abstract][Full Text] [Related]
11. N-Aryl-gamma-lactams as integrin alphavbeta3 antagonists.
Xi N; Arvedson S; Eisenberg S; Han N; Handley M; Huang L; Huang Q; Kiselyov A; Liu Q; Lu Y; Nunez G; Osslund T; Powers D; Tasker AS; Wang L; Xiang T; Xu S; Zhang J; Zhu J; Kendall R; Dominguez C
Bioorg Med Chem Lett; 2004 Jun; 14(11):2905-9. PubMed ID: 15125957
[TBL] [Abstract][Full Text] [Related]
12. Studies of tricyclic piperazine/piperidine furnished molecules as novel integrin αvβ3/αIIbβ3 dual antagonists using 3D-QSAR and molecular docking.
Yan Y; Li Y; Zhang S; Ai C
J Mol Graph Model; 2011 Feb; 29(5):747-62. PubMed ID: 21273104
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel 2,8-diazaspiro[4.5]decanes as orally active glycoprotein IIb-IIIa antagonists.
Mehrotra MM; Heath JA; Smyth MS; Pandey A; Rose JW; Seroogy JM; Volkots DL; Nannizzi-Alaimo L; Park GL; Lambing JL; Hollenbach SJ; Scarborough RM
J Med Chem; 2004 Apr; 47(8):2037-61. PubMed ID: 15056002
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel short chain 4-substituted indoles as potent alphavbeta3 antagonist using structure-based drug design.
Raboisson P; Desjarlais RL; Reed R; Lattanze J; Chaikin M; Manthey CL; Tomczuk BE; Marugán JJ
Eur J Med Chem; 2007 Mar; 42(3):334-43. PubMed ID: 17184884
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of in vivo tumour growth by the blocking of host alpha(v)beta3 and alphaII(b)beta3 integrins.
Engebraaten O; Trikha M; Juell S; Garman-Vik S; Fodstad Ø
Anticancer Res; 2009 Jan; 29(1):131-7. PubMed ID: 19331142
[TBL] [Abstract][Full Text] [Related]
16. 1,2,3,4-Tetrahydroquinoline-containing alphaVbeta3 integrin antagonists with enhanced oral bioavailability.
Ghosh S; Santulli RJ; Kinney WA; Decorte BL; Liu L; Lewis JM; Proost JC; Leo GC; Masucci J; Hageman WE; Thompson AS; Chen I; Kawahama R; Tuman RW; Galemmo RA; Johnson DL; Damiano BP; Maryanoff BE
Bioorg Med Chem Lett; 2004 Dec; 14(23):5937-41. PubMed ID: 15501072
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and initial evaluation of novel, non-peptidic antagonists of the alpha(v)-integrins alpha(v)beta(3) and alpha(v)beta(5).
Letourneau JJ; Liu J; Ohlmeyer MH; Riviello C; Rong Y; Li H; Appell KC; Bansal S; Jacob B; Wong A; Webb ML
Bioorg Med Chem Lett; 2009 Jan; 19(2):352-5. PubMed ID: 19081719
[TBL] [Abstract][Full Text] [Related]
18. Substituted benzocyloheptenes as potent and selective alpha(v) integrin antagonists.
Perron-Sierra F; Saint Dizier D; Bertrand M; Genton A; Tucker GC; Casara P
Bioorg Med Chem Lett; 2002 Nov; 12(22):3291-6. PubMed ID: 12392735
[TBL] [Abstract][Full Text] [Related]
19. Orally active isoxazoline glycoprotein IIb/IIIa antagonists with extended duration of action.
Olson RE; Sielecki TM; Wityak J; Pinto DJ; Batt DG; Frietze WE; Liu J; Tobin AE; Orwat MJ; Di Meo SV; Houghton GC; Lalka GK; Mousa SA; Racanelli AL; Hausner EA; Kapil RP; Rabel SR; Thoolen MJ; Reilly TM; Anderson PS; Wexler RR
J Med Chem; 1999 Apr; 42(7):1178-92. PubMed ID: 10197962
[TBL] [Abstract][Full Text] [Related]
20. Discrete functional motifs reside within the cytoplasmic tail of alphaV integrin subunit.
Haas TA
Thromb Haemost; 2008 Jan; 99(1):96-107. PubMed ID: 18217140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]